319 related articles for article (PubMed ID: 30456564)
1. Effect of vitamin D treatment in children with attention-deficit hyperactivity disorder.
Dehbokri N; Noorazar G; Ghaffari A; Mehdizadeh G; Sarbakhsh P; Ghaffary S
World J Pediatr; 2019 Feb; 15(1):78-84. PubMed ID: 30456564
[TBL] [Abstract][Full Text] [Related]
2. Effect of vitamin D supplementation as adjunctive therapy to methylphenidate on ADHD symptoms: A randomized, double blind, placebo-controlled trial.
Mohammadpour N; Jazayeri S; Tehrani-Doost M; Djalali M; Hosseini M; Effatpanah M; Davari-Ashtiani R; Karami E
Nutr Neurosci; 2018 Apr; 21(3):202-209. PubMed ID: 27924679
[TBL] [Abstract][Full Text] [Related]
3. Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial.
Kean JD; Sarris J; Scholey A; Silberstein R; Downey LA; Stough C
Psychopharmacology (Berl); 2017 Feb; 234(3):403-420. PubMed ID: 27921139
[TBL] [Abstract][Full Text] [Related]
4. Impact of Vitamin D Supplementation on Attention-Deficit Hyperactivity Disorder in Children.
Elshorbagy HH; Barseem NF; Abdelghani WE; Suliman HAI; Al-Shokary AH; Abdulsamea SE; Elsadek AE; Abdel Maksoud YH; Nour El Din DMAE
Ann Pharmacother; 2018 Jul; 52(7):623-631. PubMed ID: 29457493
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
6. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
[TBL] [Abstract][Full Text] [Related]
8. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder.
Jain R; Segal S; Kollins SH; Khayrallah M
J Am Acad Child Adolesc Psychiatry; 2011 Feb; 50(2):171-9. PubMed ID: 21241954
[TBL] [Abstract][Full Text] [Related]
9. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
Boellner SW; Earl CQ; Arora S
Curr Med Res Opin; 2006 Dec; 22(12):2457-65. PubMed ID: 17257460
[TBL] [Abstract][Full Text] [Related]
10. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371].
Akhondzadeh S; Mohammadi MR; Khademi M
BMC Psychiatry; 2004 Apr; 4():9. PubMed ID: 15070418
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Vitamin D Supplementation on Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Gan J; Galer P; Ma D; Chen C; Xiong T
J Child Adolesc Psychopharmacol; 2019 Nov; 29(9):670-687. PubMed ID: 31368773
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
[TBL] [Abstract][Full Text] [Related]
14. Self-inserted foreign body and attention-deficit/hyperactivity disorder: evaluated by the Conners' Parent Rating Scales-Revised.
Özcan K; Özcan Ö; Muluk NB; Cingi C; Durukan K
Int J Pediatr Otorhinolaryngol; 2013 Dec; 77(12):1992-7. PubMed ID: 24139587
[TBL] [Abstract][Full Text] [Related]
15. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study.
Biederman J; Swanson JM; Wigal SB; Boellner SW; Earl CQ; Lopez FA;
J Clin Psychiatry; 2006 May; 67(5):727-35. PubMed ID: 16841622
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.
Greenhill LL; Findling RL; Swanson JM;
Pediatrics; 2002 Mar; 109(3):E39. PubMed ID: 11875167
[TBL] [Abstract][Full Text] [Related]
17. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
[TBL] [Abstract][Full Text] [Related]
18. An Open-label, Self-control, Prospective Study on Cognitive Function, Academic Performance, and Tolerability of Osmotic-release Oral System Methylphenidate in Children with Attention-deficit Hyperactivity Disorder.
Zheng Y; Liang JM; Gao HY; Yang ZW; Jia FJ; Liang YZ; Fang F; Li R; Xie SN; Zhuo JM
Chin Med J (Engl); 2015 Nov; 128(22):2988-97. PubMed ID: 26608976
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.
Chronis-Tuscano A; Seymour KE; Stein MA; Jones HA; Jiles CD; Rooney ME; Conlon CJ; Efron LA; Wagner SA; Pian J; Robb AS
J Clin Psychiatry; 2008 Dec; 69(12):1938-47. PubMed ID: 19192455
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D deficiency in school-age Iranian children with attention-deficit/hyperactivity disorder (ADHD) symptoms: A critical comparison with healthy controls.
Fasihpour B; Moayeri H; Shariat M; Keihanidoust Z; Effatpanah M; Khedmat L
Child Neuropsychol; 2020 May; 26(4):460-474. PubMed ID: 31514566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
